Cross‑Sectional Analysis of Pregnancy Labeling: When “Limited Data” Unjustifiably Becomes a Global Barrier to Necessary Treatment for Pregnant Women
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Abstract Prescribing information (PI) serves as the primary regulatory guidance for clinicians treating pregnant women, yet often lacks comprehensive pregnancy data, leading authorities to adopt restrictive language or default contraindications. This cross-sectional study assessed consistency in pregnancy risk communication across five major regulatory authorities: FDA, EMA, TGA, Canada and MHRA. Latest PIs were obtained from official databases of the five regulatory authorities. Only English-language PIs available for at least four authorities were included. Each PI was evaluated for pregnancy contraindications, reported risks (miscarriages, major malformations), and overall tone (permissive/restrictive). McNemar and Fleiss' multi-rater Kappa methods were used to assess the authorities' agreement level. Pregnancy contraindications on EMA, TGA, Canada, and MHRA labels ranged from 18.7%, 20.1%, 23.1%, 21.8%, respectively, versus 7.4% on FDA labels (P
Fields of Study & Subjects
Pregnancy and Medication Impact
Pharmacovigilance and Adverse Drug Reactions
Biomedical Ethics and Regulation
Publication details
- Journal / source
- Research Square
- Publication date
- 27 March 2026
- Language
- EN
- Document type
- Preprint